10.2 Long-Term Management of Chronic Cardiovascular Diseases

10.2 Long-Term Management of Chronic Cardiovascular Diseases

[!NOTE] ANCC Blueprint Alignment: Domain II (Planning, Implementation, and Outcome Evaluation) tests advanced registered nursing competence in optimizing long-term pharmacotherapy for chronic coronary disease, managing outpatient guideline-directed medical therapy (GDMT) in heart failure, categorizing and pharmacologically treating chronic hypertension, directing peripheral vascular maintenance, and managing outpatient anticoagulation clinics.

Outpatient cardiovascular care centers on longitudinal disease stabilization, preventing rehospitalizations, halting adverse structural cardiac remodeling, and minimizing ischemic vascular complications. Registered nurses serve as frontline clinical coordinators, titrating complex drug regimens and monitoring therapeutic efficacy.

Chronic Coronary Disease (CCD) & Stable Ischemic Heart Disease

Chronic Coronary Disease (formerly termed stable ischemic heart disease or chronic stable angina) is characterized by a predictable, transient mismatch between myocardial oxygen supply and myocardial oxygen demand, precipitated by physical exertion, cold weather, or emotional stress, and reliably relieved by rest or sublingual nitroglycerin within 2 to 5 minutes.

Anti-Anginal Pharmacotherapy: Mechanisms & Clinical Titration

Medical management of CCD addresses two parallel objectives: symptom alleviation / angina reduction and secondary prevention of acute myocardial infarction and death.

Secondary Prevention Regimen in CCD

1. Antiplatelet Therapy: Low-dose aspirin (81 mg PO daily) indefinitely to inhibit platelet cyclooxygenase-1 ($TXA_2$ synthesis). In patients with severe aspirin allergy or gastrointestinal intolerance, clopidogrel 75 mg daily is substituted.
2. High-Intensity Statin Therapy: Mandatory for all patients with CCD regardless of baseline lipid levels: Atorvastatin 40 to 80 mg daily or Rosuvastatin 20 to 40 mg daily (targeting $\ge 50%$ LDL reduction and an absolute target $LDL-C < 70\text{ mg/dL}$, or $<55\text{ mg/dL}$ in very high-risk disease).
3. Renin-Angiotensin-Aldosterone System (RAAS) Inhibition: ACE inhibitors or ARBs are strongly recommended if the patient has concurrent hypertension, diabetes mellitus, left ventricular systolic dysfunction ($LVEF \le 40%$), or chronic kidney disease (CKD).
4. Preventive Vaccinations: Annual seasonal influenza vaccination and updated pneumococcal and COVID-19 vaccinations to prevent systemic inflammatory triggers of plaque rupture.

Long-Term Outpatient Heart Failure Management Across the Lifespan

Guideline-Directed Medical Therapy (GDMT) for Heart Failure with reduced Ejection Fraction (HFrEF, $LVEF \le 40%$) is anchored by four foundational medication classes termed the "Four Pillars". When fully optimized, this quadruple therapy reduces 2-year all-cause mortality by over 60% to 70% and reduces hospital readmissions dramatically.

                    [ THE FOUR PILLARS OF OUTPATIENT GDMT FOR HFrEF ]
                                           │
         ┌───────────────────┬─────────────┴─────────────┬───────────────────┐
         ▼                   ▼                           ▼                   ▼
   [ PILLAR 1 ]        [ PILLAR 2 ]                [ PILLAR 3 ]        [ PILLAR 4 ]
  ARNI / ACEI / ARB   BETA-BLOCKER                MRA                 SGLT2 INHIBITOR
  Sacubitril/Valsartan Carvedilol (3.125-25 mg)   Spironolactone      Dapagliflozin 10 mg
  (Preferred over ACEI) Metoprolol Succinate       (12.5-25 mg QD)     Empagliflozin 10 mg
  *MANDATORY 36-HR     (12.5-200 mg QD)           or Eplerenone       Fixed single dose;
  WASHOUT FROM ACEI*  Bisoprolol (1.25-10 mg)    Monitor K+, Cr      no titration needed

1. The Four Foundational Pillars

• Pillar 1: Angiotensin Receptor-Neprilysin Inhibitor (ARNI): Sacubitril/valsartan (Entresto) is preferred over ACE inhibitors or ARBs based on the PARADIGM-HF trial. Sacubitril inhibits neprilysin (neutral endopeptidase), preventing the enzymatic breakdown of endogenous natriuretic peptides (ANP, BNP, CNP, bradykinin, and adrenomedullin), promoting natriuresis, vasodilation, and anti-fibrotic remodeling, while valsartan selectively blocks the $AT_1$ receptor.
• Pillar 2: Evidence-Based Beta-Blockers: Strictly limited to three clinical agents proven to reduce mortality in HFrEF: Carvedilol, Metoprolol Succinate extended-release, and Bisoprolol. Short-acting metoprolol tartrate, atenolol, and propranolol do NOT confer mortality benefits and must not be used for HFrEF. Beta-blockers must be initiated at very low doses only in hemodynamically stable, euvolemic patients and titrated every 2 weeks.
• Pillar 3: Mineralocorticoid Receptor Antagonists (MRAs): Spironolactone (12.5 to 25 mg daily) or eplerenone (25 to 50 mg daily). Blocks aldosterone receptors in the cortical collecting duct and cardiac fibroblasts, halting myocardial collagen deposition and fibrosis. Requires baseline serum potassium $<5.0\text{ mEq/L}$ and estimated $GFR > 30\text{ mL/min/1.73 m}^2$.
• Pillar 4: Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: Dapagliflozin (10 mg daily) or Empagliflozin (10 mg daily). Promotes osmotic diuresis, decreases intraglomerular pressure, improves myocardial bioenergetics, and suppresses sympathetic overdrive. Benefits occur independent of the presence of diabetes mellitus and extend to HF with preserved ejection fraction (HFpEF).

[!CAUTION] The Mandatory 36-Hour Washout Period Between ACEI and ARNI: When switching a patient from an ACE inhibitor (e.g., lisinopril, enalapril) to an ARNI (sacubitril/valsartan), the registered nurse must verify that the ACE inhibitor has been completely discontinued for at least 36 hours before administering the first dose of sacubitril/valsartan. Both ACE (kininase II) and neprilysin degrade bradykinin. Dual concurrent inhibition causes massive, uncontrolled systemic bradykinin accumulation, precipitating catastrophic, life-threatening angioedema of the tongue, pharynx, and upper airway.

Transitions of Care & Outpatient Titration Workflow

• Rapid Sequence Initiation: Rather than titrating one drug to maximum dose before starting the next, contemporary guidelines recommend initiating all four pillars simultaneously or in rapid succession at low starting doses within the first 2 to 4 weeks of diagnosis or post-discharge.
• Post-Discharge Follow-Up: The "vulnerable phase" occurs within the first 30 days post-hospital discharge. A follow-up cardiology visit must occur within 7 to 14 days of discharge, coupled with a telephone check-in within 48 to 72 hours to assess weight logs, volume status, and renal chemistries.
• Laboratory Surveillance: Check serum potassium, BUN, and serum creatinine at 1 to 2 weeks after any dose initiation or titration of an ARNI, ACEI, ARB, or MRA. An elevation in serum creatinine of up to 20% to 30% is physiologically acceptable and reflects altered intraglomerular hemodynamics rather than true structural nephron damage.

Chronic Hypertension: Categories & First-Line Pharmacotherapy

Chronic hypertension is the single most common modifiable risk factor for stroke, coronary artery disease, heart failure, and chronic kidney disease. The 2017 ACC/AHA High Blood Pressure Clinical Practice Guidelines established rigorous blood pressure categories and therapeutic targets.

2017 ACC/AHA Blood Pressure Staging for Adults

[!IMPORTANT] Target Blood Pressure Across All Adults: The recommended target blood pressure for all non-institutionalized ambulatory adult patients with confirmed hypertension (including those with diabetes mellitus, chronic kidney disease, or advanced age) is $< 130/80\text{ mmHg}$.

First-Line Antihypertensive Drug Selection

Guidelines establish four primary first-line classes: Thiazide/Thiazide-like diuretics, Calcium Channel Blockers (CCBs), ACE Inhibitors, and Angiotensin Receptor Blockers (ARBs).

1. General Non-Black Population: Any of the four classes may be initiated as monotherapy or in combination.
2. Black Adult Population (Without CKD or HF): Initial antihypertensive therapy should comprise a Thiazide-type diuretic or a Dihydropyridine CCB (e.g., amlodipine or chlorthalidone) rather than an ACEI or ARB. Low-renin hypertension is prevalent in this cohort; monotherapy with ACEI/ARBs demonstrates inferior blood pressure reduction and higher stroke rates unless paired with a CCB or diuretic.
3. Chronic Kidney Disease (CKD Stage 3+ or Proteinuria $\ge 300\text{ mg/day}$): An ACE inhibitor or ARB is mandatory first-line therapy (regardless of race or diabetic status) to decrease intraglomerular efferent arteriolar pressure and arrest proteinuria progression.
4. Chlorthalidone vs. Hydrochlorothiazide (HCTZ): Chlorthalidone is preferred over HCTZ due to its prolonged terminal elimination half-life (40 to 60 hours vs. 6 to 12 hours) and proven cardiovascular event reduction in landmark clinical trials (ALLHAT).

Peripheral Vascular Disease Chronic Maintenance

Peripheral arterial disease (PAD) and chronic venous insufficiency (CVI) represent distinct circulatory pathologies requiring opposite physiological management.

Peripheral Artery Disease (PAD): Diagnosis & Conservative Maintenance

PAD results from progressive atherosclerotic narrowing of non-cardiac, non-intracranial arteries, most frequently affecting the femoropopliteal, aortoiliac, and infrapopliteal vessels.

• Diagnostic Standard: Ankle-Brachial Index (ABI):
  • Ratio of highest systolic blood pressure at the ankle (dorsalis pedis or posterior tibial) to highest systolic blood pressure in either arm ($ABI = \text{Ankle SBP} / \text{Brachial SBP}$).
  • Normal ABI: 1.00 to 1.40.
  • Borderline ABI: 0.91 to 0.99.
  • Mild-to-Moderate PAD (Intermittent Claudication): 0.41 to 0.90.
  • Severe PAD / Critical Limb-Threatening Ischemia (Rest Pain, Ulcers): $\le 0.40$.
  • Non-Compressible Calcified Vessels: $> 1.40$ (frequently seen in advanced diabetes and end-stage renal disease; requires Toe-Brachial Index [TBI] testing, where normal is $\ge 0.70$).
• Pharmacological Maintenance:
  • Antiplatelet therapy: Aspirin 81 mg daily or Clopidogrel 75 mg daily.
  • Vascular Protection (COMPASS trial): Low-dose Rivaroxaban 2.5 mg BID plus Aspirin 81 mg daily reduces major adverse limb events (amputation) and cardiovascular death in symptomatic PAD.
  • High-Intensity Statin: Mandatory (Atorvastatin 80 mg or Rosuvastatin 40 mg).
  • Cilostazol (Pletal): Phosphodiesterase-3 (PDE-3) inhibitor; promotes arterial vasodilation and suppresses platelet aggregation, improving pain-free walking distance. STRICT BLACK BOX CONTRAINDICATION: Cilostazol is absolutely contraindicated in patients with heart failure of any severity or reduced ejection fraction, as PDE-3 inhibition increases intracellular cyclic AMP, triggering fatal ventricular tachydysrhythmias.
• Supervised Exercise Therapy (SET): The gold-standard non-pharmacological therapy. Patients walk on a treadmill until moderate-to-severe claudication pain occurs, rest until pain completely resolves, and resume walking. Sessions last 30 to 45 minutes, 3 to 5 times per week, for at least 12 weeks. SET stimulates collateral arteriolar angiogenesis, improves endothelial flow-mediated vasodilation, and doubles pain-free walking capacity.
• Foot Care Instructions: Daily visual foot inspection using a floor mirror, wear seamless moisture-wicking socks and well-fitted protective shoes, never walk barefoot, cut toenails straight across, and never apply heating pads or hot water bottles to feet (neuropathic thermal burns cause rapid gangrene).

Chronic Venous Insufficiency (CVI) Maintenance

Unlike PAD (arterial insufficiency requiring dependent limb positioning), CVI involves incompetent venous valves, calf muscle pump failure, and chronic venous hypertension.

• Graduated Compression Therapy: Knee-high or thigh-high medical compression stockings delivering 20 to 30 mmHg (mild-moderate) or 30 to 40 mmHg (severe) pressure. Applied first thing in the morning before dependent edema accumulates. Caution: Strictly contraindicated if severe co-existing PAD is present ($ABI \le 0.50$).
• Leg Elevation: Elevate lower extremities above the level of the right atrium for 30 minutes, 3 to 4 times daily, and avoid prolonged standing or sitting with legs crossed.

Outpatient Anticoagulation Clinics & INR Management

Cardiovascular nurses manage specialized outpatient anticoagulation services, balancing thromboembolic prevention against bleeding risks.

Warfarin vs. Direct Oral Anticoagulants (DOACs)

• DOACs (Apixaban, Rivaroxaban, Dabigatran, Edoxaban): First-line for non-valvular atrial fibrillation and deep vein thrombosis (DVT) / pulmonary embolism (PE). They do not require routine INR monitoring, have fixed dosing, short half-lives, and significantly lower rates of fatal intracranial hemorrhage.
• Warfarin (Coumadin): Mandatory and irreplaceable in patients with:
  1. Mechanical Prosthetic Heart Valves (aortic or mitral).
  2. Moderate-to-Severe Mitral Stenosis (rheumatic etiology).
  3. Antiphospholipid Antibody Syndrome (APS).

Target INR Ranges & Monitoring Benchmarks

• Standard Target INR 2.0 to 3.0 (Goal 2.5): Non-valvular atrial fibrillation, treatment/prevention of DVT and PE, bioprosthetic tissue valves, and mechanical bileaflet aortic valves without thromboembolic risk factors.
• High-Intensity Target INR 2.5 to 3.5 (Goal 3.0): Mechanical Mitral Valves, mechanical aortic valves with high-risk features (atrial fibrillation, severe LV dysfunction, prior thromboembolism), or caged-ball / tilting-disc mechanical valves.
• Quality Metric: Time in Therapeutic Range (TTR): Optimal anticoagulation clinic management targets a $\text{TTR} \ge 65%\text{ to }70%$ using the Rosendaal method. Low TTR ($<60%$) correlates with higher rates of both ischemic stroke and major bleeding.
• Dietary Vitamin K Education: The nurse must instruct patients to maintain a consistent daily dietary intake of Vitamin K-rich foods (spinach, kale, collard greens, broccoli, Brussels sprouts). Patients should NOT eliminate green leafy vegetables; rather, avoiding abrupt fluctuations ensures steady hepatic coagulation factor synthesis.
• Management of Supratherapeutic INR Without Bleeding:
  • $\text{INR } 4.5\text{ to }10.0$ without bleeding: Hold 1 to 2 doses of warfarin, monitor INR, and resume at a reduced maintenance dose once therapeutic. Routine vitamin K is not recommended.
  • $\text{INR } > 10.0$ without bleeding: Hold warfarin and administer **oral Vitamin } K_1$ (phytonadione 2.5 to 5 mg PO).